Aradigm
HomeAboutProductsTechnologiesInvestorsCareers
News & Events

Press Releases

Upcoming Events

Media Contact:
Nancy Pecota
Chief Financial Officer
Assistant: Rita Mateo
Phone: 510-265-8800
E-mail: investor@aradigm.com

Latest News

Aradigm to Host Analyst Meeting and Webcast on August 12 in New York City
Aug 6, 2014
[06AUG14
]

Aradigm to Host Corporate Update Conference Call on June 26
[25JUN14
]

Aradigm Corporation Announces the Dosing of the First Patient in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-4)
[23JUN14
]

Aradigm Receives $5 Million Milestone For Dosing of the First Patient in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis
[03JUN14
]

On May 23, 2014, the Company effected the reverse split of all outstanding Common Stock approved by shareholders on April 18, 2014. The split ratio is 40 to 1. The temporary trading symbol of Aradigm Common Storck is ARDMD. The Company's Form 8937 contains more information concerning this organizational action and its effect on the tax basis of the securities.
[27MAY14
]

FDA Grants QIDP Designation to Aradigm's Inhaled Antibiotic
[20MAY14
]

Aradigm Announces First Quarter 2014 Financial Results
[14MAY14
]

Aradigm Corporation Announces the Dosing of the First Patient in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-3)
[30APR14
]

Results from Non-Tuberculous Mycobacteria (NTM) Study Using Aradigm's Liposomal Ciprofloxacin to be Presented at the American Thoracic Society 2014 International Conference
[15APR14
]

Aradigm Announces Fourth Quarter 2013 and Full Year Financial Results
[04FEB14
]

Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2014 on February 11
[04FEB14
]

Aradigm to Present at Biotech Showcase 2014 on January 14
[28JAN14]

Aradigm Announces Appointment of Dr. Juergen Froehlich as Chief Medical Officer
[19NOV13
]

Aradigm Announces Third Quarter 2013 Financial Results
[28OCT13
]

Aradigm Announces Changes to its Board of Directors
[18SEP13
]

Sigma-Tau PharmaSource, Inc. and Aradigm Corporation Sign Manufacturing Agreement for the Clinical and Commercial Supply of Pulmaquin
[16SEP13
]

Aradigm to Present at the Stifel Nicolaus 2013 Healthcare Conference
[09SEP13
]

Grifols and Aradigm Corporation Complete the Closing of Worldwide Licensing Agreement to Develop and Commercialize Pulmaquin®
[28AUG13
]

Aradigm Announces Second Quarter 2013 Financial Results
[08AUG13
]

Aradigm Awarded NIH Grant to Investigate the Treatment of Pulmonary Non-Tuberculous Mycobacterial (PNTM) Infections with Pulmaquin and Lipoquin
[07AUG13
]

Aradigm Shareholders Approve Collaboration Transaction With Grifols, S.A. to Develop and Commercialize Pulmaquin
[16JUL13
]

Grifols, S.A. and Aradigm Corporation Announce Signing of Worldwide Licensing Agreement to Develop and Commercialize Pulmaquin™
[21MAY13
]

Aradigm Announces First Quarter 2013 Financial Results
[14MAY13
]

Aradigm Announces Fourth Quarter 2012 and Full Year Financial Results
[26MAR12
]

Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2013 on February 12
[06FEB12
]

Aradigm to Present at Biotech Showcase 2013 on January 9
[12DEC12
]

Aradigm Announces Private Placement for $6 Million
[12DEC12
]

UK Scientists Report on Efficacy of Aradigm's Lipoquin™ Against Pneumonic Plague
[10DEC12
]

Aradigm Announces Third Quarter 2012 Financial Results
[08NOV12
]

Virginia Commonwealth University Scientists Report Anti-Inflammatory Effect of Aradigm's Inhaled Liposomal Ciprofloxacin
[18OCT12
]

UK Scientists Report Successful Testing of Aradigm's Inhaled Liposomal Ciprofloxacin in Q Fever
[20SEP12
]

New U.S. Composition of Matter Patent for Aradigm's Pulmaquin™ and Lipoquin™ Provides Protection Until 2031
[18SEP12
]

Aradigm Patent Protection for Smoking Cessation is Extended with Issuance of a Method of Treatment Patent
[05SEP12
]

Aradigm to Participate in FDA Workshop on Non-Cystic Fibrosis Bronchiectasis
[30AUG12
]

Aradigm to Present at the Stifel Nicolaus 2012 Healthcare Conference
[29AUG12
]

Aradigm Announces Second Quarter 2012 Financial Results
[09AUG12
]

Aradigm Announces First Quarter 2012 and Full Year Financial Results
[11MAY12
]

Aradigm Announces Fourth Quarter 2011 and Full Year Financial Results
[27MAR12
]

Aradigm Receives U.S. FDA Clearance for Phase 3 Clinical Trial of Pulmaquin™ in Patients with Non-Cystic Fibrosis Bronchiectasis
[12MAR12
]

US Patent Protection for Pulmaquin™ Is Extended with Issuance of a Composition of Matter Patent
[21FEB12
]

Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2012 on February 13
[08FEB12
]

Aradigm to Present at Biotech Showcase 2012 on January 9
[05JAN12
]

Aradigm Selects Pulmaquin™ for Phase 3 Development and Announces Issuance of Its First U.S. Patent Covering Inhaled Ciprofloxacin Formulations
[07DEC11
]

Aradigm Announces Third Quarter 2011 Financial Results
[10NOV11
]

Aradigm to Present at the 10th Annual BIO Investor Forum on October 26
[20OCT11
]

Aradigm Presents Additional Analyses of the Clinical Results From ORBIT-1 and ORBIT-2 Trials of Inhaled Ciprofloxacin at the 2011 European Respiratory Society (ERS) Annual Congress
[21SEP11
]

Aradigm to Present at Rodman & Renshaw Annual Global Investment Conference
[07SEP11
]

Aradigm Announces Second Quarter 2011 Financial Results
[09AUG11
]

Aradigm Announces Private Placement for $4.75 Million
[06JUL11
]

Aradigm Enters $8.5 Million Royalty Financing Agreement With PBS Capital Management LLC
[22JUN11
]

Aradigm Reports Successful ORBIT-1 Bronchiectasis Study with Inhaled Liposomal Ciprofloxacin
[16JUN11
]

Aradigm Receives FDA Orphan Drug Designation for Ciprofloxacin for Inhalation in Bronchiectasis
[06JUN11
]

Aradigm Announces First Quarter 2011 Financial Results
[12MAY11
]

Aradigm to Present Additional ORBIT-2 Clinical Trial Results at Respiratory Drug Delivery Europe 2011 Conference
[03MAY11
]

Aradigm Announces Fourth Quarter 2010 and Full Year Financial Results
[24MAR11
]

Aradigm Completes Enrollment in Phase 2b Study of Inhaled Ciprofloxacin for the Management of Respiratory Infections in Bronchiectasis
[22MAR11
]

Aradigm to Present at ROTH Capital Partners 23rd Annual OC Growth Stock Conference
[10MAR11
]

Aradigm to Present at the 13th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference
[10FEB11
]

SUMAVEL DosePro Receives Marketing Approval in Germany and the United Kingdom
[11JAN11
]

Aradigm to Report Expanded Results from Successful Six-Month Phase 2b Bronchiectasis Study at Biotech Showcase 2011
[06JAN11
]

SUMAVEL DosePro is Granted First European Approval
[07DEC10
]

Aradigm Announces Third Quarter 2010 Financial Results
[11NOV10
]

Aradigm Appoints Tamar Howson to Board of Directors
[04NOV10
]

Aradigm Awarded Three Therapeutic Discovery Tax Credit Grants Totaling Over $733,000 for Inhaled Liposomal Ciprofloxacin Program
[02NOV10
]

Aradigm Reports Successful Phase 2b Bronchiectasis Study with Inhaled Liposomal Ciprofloxacin
[20OCT10
]

Aradigm to Present at the 9th Annual BIO Investor Forum on )ctober 6
[04OCT10
]

Aradigm CEO Igor Gonda to Be Featured Guest Interview on StockGoodies.com Radio on September 30
[30SEP10
]

Aradigm Announces Exercise of Warrants for Proceeds of Approximately $891,000
[23SEP10
]

Aradigm Closes Equity for Debt Transaction with Novo Nordisk A/S
[20SEP10
]

Aradigm Presents Results Supporting Once-Daily Dosing With Its Inhaled Liposomal Ciprofloxacin Formulations at the 2010 European Respiratory Society (ERS) Annual Congress
[17SEP10
]

Aradigm Announces Second Quarter 2010 Financial Results
[12AUG10
]

Aradigm Announces Equity for Debt Transaction with Novo Nordisk
[02AUG10
]

Aradigm Announces Private Placement for $5 Million
[21JUN10
]

Aradigm Presents at the 2010 International Conference of the American Thoracic Society
[17MAY10
]

Aradigm Announces First Quarter 2010 Financial Results
[13MAY10
]

Aradigm Receives FDA Clearance for Clinical Trial of Inhaled Liposomal Ciprofloxacin in Pediatric Patients With Cystic Fibrosis
[05MAY10
]

Aradigm Completes Enrollment and Doses Last Patient in Long Term Phase 2 Study of a Novel Inhaled Ciprofloxacin Formulation for the Management of Respiratory Infections in Bronchiectasis
[25MAR10
]

Aradigm Announces Fourth Quarter 2009 and Full Year Financial Results
[23MAR10
]

Aradigm Doses First Patient in Its Second Phase 2b Clinical Trial of Inhaled Liposomal Ciprofloxacin in Bronchiectasis Patients
[23FEB10
]

Aradigm Receives $4 Million Milestone Payment Upon First Commercial Sale of SUMAVEL* DosePro*
[04FEB10
]

Aradigm to Present at Biotech Showcase 2010 on January 12
[06JAN10
]

Aradigm to Present at the Lippert/Heilshorn Life Sciences Virtual Conference
[10DEC09]

Aradigm Doses First Patient in Long-Term Phase 2 Study of a Novel Inhaled Ciprofloxacin Formulation for the Management of Respiratory Infections in Bronchiectasis
[16NOV
09]

Aradigm Announces Third Quarter 2009 Financial Results
[14SEP
09]

Aradigm to Present at the 8th Annual BIO Investor Forum on October 28
[22OCT
09]

Aradigm Presents Data Demonstrating Significant Antibacterial Concentrations and Effects in Non-Cystic Fibrosis Bronchiectasis Patients Following Administration of its Once-Daily Inhaled Liposomal Ciprofloxacin
[14SEP
09]

Aradigm Announces Second Quarter 2009 Financial Results
[06AUG
09]

Aradigm Receives Orphan Drug Designation for Inhaled Liposomal Ciprofloxacin to Treat Cystic Fibrosis in Europe
[05AUG
09]

Zogenix Announces Exclusive Co-Promotion Agreement in U.S. for Sumavel(TM) DosePro(TM)
[04AUG
09]

Aradigm Receives FDA Clearance for Phase IIb Clinical Trial of Inhaled Liposomal Ciprofloxacin to Treat Bronchiectasis
[23JUL
09]

Zogenix Obtains Approval in U.S. for Sumavel(TM) DosePro(TM)
[16JUN
09]

Upcoming Events
For a listing of Upcoming Events click here.

 

 

 

 

 

 

 

CONTACT NEWS & EVENTS LEGAL SITE MAP ©2013 Aradigm Corporation. All Rights Reserved.